Abstract
Background: In the past few years, great of attention has been paid to the identification and characterization of selective and potent inhibitors of the first identified histone demethylase LSD1, which may erase mono- and di-methylated histone 3 lysine 4 and 9. As the aberrant overexpression of LSD1 is involved in various pathological processes, especially cancer, obtaining selective and potent LSD1 inhibitors has emerged as a crucial issue in medicinal chemistry research.
Method: Until now, several LSD1 inhibitor screening models have been established, including enzyme coupled assay, LC-MS based assay, and FRET based assay. Nevertheless, due to some special instrument requirement and additional costs of LC-MS and FRET, the enzyme coupled assay is the most widely applied method for LSD1 inhibitor screening. Result: We summarized and compared several reported in vitro LSD1 inhibitor screening models. Each of them has distinct advantages and disadvantages, and none of these methods is perfect. In order to exclude the false positive results, at least one additional method should be applied to screen LSD1 inhibitors.Keywords: LSD1, inhibitor, screening model, enzyme coupled assay, LC-MS, FRET.
Current Medicinal Chemistry
Title:An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors
Volume: 24 Issue: 23
Author(s): Yi-Chao Zheng, Jiao Chang, Ting Zhang , Feng-Zhi Suo , Xiao-Bing Chen, Ying Liu , Bing Zhao, Bin Yu*Hong-Min Liu*
Affiliation:
- School of Pharmaceutical Sciences, Zhengzhou University, P.O. Box: 450001, Zhengzhou,China
- School of Pharmaceutical Sciences, Zhengzhou University, P.O. Box: 450001, Zhengzhou,China
Keywords: LSD1, inhibitor, screening model, enzyme coupled assay, LC-MS, FRET.
Abstract: Background: In the past few years, great of attention has been paid to the identification and characterization of selective and potent inhibitors of the first identified histone demethylase LSD1, which may erase mono- and di-methylated histone 3 lysine 4 and 9. As the aberrant overexpression of LSD1 is involved in various pathological processes, especially cancer, obtaining selective and potent LSD1 inhibitors has emerged as a crucial issue in medicinal chemistry research.
Method: Until now, several LSD1 inhibitor screening models have been established, including enzyme coupled assay, LC-MS based assay, and FRET based assay. Nevertheless, due to some special instrument requirement and additional costs of LC-MS and FRET, the enzyme coupled assay is the most widely applied method for LSD1 inhibitor screening. Result: We summarized and compared several reported in vitro LSD1 inhibitor screening models. Each of them has distinct advantages and disadvantages, and none of these methods is perfect. In order to exclude the false positive results, at least one additional method should be applied to screen LSD1 inhibitors.Export Options
About this article
Cite this article as:
Zheng Yi-Chao , Chang Jiao , Zhang Ting, Suo Feng-Zhi , Chen Xiao-Bing , Liu Ying , Zhao Bing , Yu Bin *, Liu Hong-Min*, An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors, Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170509114321
DOI https://dx.doi.org/10.2174/0929867324666170509114321 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
Current Gene Therapy Origins, Structures, and Bioactivities of Secondary Metabolites from Marine-derived Penicillium Fungi
Mini-Reviews in Medicinal Chemistry G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Promises.
Current Cancer Drug Targets Withdrawal Notice: Application of Nanomaterials in Development of Electrochemical Sensors and Drug Delivery Systems for Anticancer Drugs
Current Drug Delivery Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation
Anti-Cancer Agents in Medicinal Chemistry The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design About a Long Lasting Primary Pleomorphic Adenoma of the Lung with a Misleading Pattern
Current Respiratory Medicine Reviews Meet the Editorial Board:
Anti-Cancer Agents in Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Topical Delivery of Antioxidants
Current Drug Delivery Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry FDG-PET/CT for Systemic Infections
Current Molecular Imaging (Discontinued)